Nkarta/NKTX

$6.54

-2.82%
-
1D1W1MYTD1YMAX

About Nkarta

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.

Ticker

NKTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Paul Hastings

Employees

150

Headquarters

South san francisco, United States

Nkarta Metrics

BasicAdvanced
$460M
Market cap
-
P/E ratio
-$2.35
EPS
0.86
Beta
-
Dividend rate
$460M
0.8583
$16.24
$1.28
1M
19.955
-22.45%
-28.33%
-23.55%
0.971
0.972
5.74%

What the Analysts think about Nkarta

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 8 analysts.
186.7% upside
High $25.00
Low $13.00
$6.54
Current price
$18.75
Average price target

Nkarta Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$30M
6.5%
Profit margin
0%
NaN%

Nkarta Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.84%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.68
-$0.52
-$0.57
-$0.58
-
Expected
-$0.68
-$0.67
-$0.59
-$0.56
-$0.44
Surprise
0%
-22.82%
-3.59%
3.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Nkarta stock?

Nkarta (NKTX) has a market cap of $460M as of May 22, 2024.

What is the P/E ratio for Nkarta stock?

The price to earnings (P/E) ratio for Nkarta (NKTX) stock is 0 as of May 22, 2024.

Does Nkarta stock pay dividends?

No, Nkarta (NKTX) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next Nkarta dividend payment date?

Nkarta (NKTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Nkarta?

Nkarta (NKTX) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Nkarta stock price target?

The target price for Nkarta (NKTX) stock is $18.75, which is 187.14% above the current price of $6.53. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Nkarta stock

Buy or sell Nkarta stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing